🦠 Macrophage type 1-derived extracellular vesicles were isolated and combined with PLGA nanoparticles loaded with the TLR3 agonist poly I:C as a therapeutic strategy to investigate their antitumor activity against breast cancer. 🔗 bit.ly/3GisIua

💉 Scientists found a diaryl piperidone-sulfonamide derivative that increases the levels of reactive oxygen species and lipid peroxides in MDA-MB-231 cells, thereby inducing ferroptosis, providing a novel therapeutic strategy for the treatment of TNBC. 🔗 bit.ly/3GmKxZ5

🚦 Dr. Subhrajit Banerjee and team at UT Southwestern Medical Center show that BLTP2 regulates plasma membrane (PM) fluidity by increasing phosphatidylethanolamine levels in the PM. 🔓 Nature Cell Biology | go.nature.com/3IbsbL4

📉 Dr. Gourish Mondal and team at UC San Francisco show that autophagy normally suppresses breast cancer #metastasis by enabling the clearance of NBR1–p62/SQSTM1 complexes that instruct p63-mediated pro-metastatic basal differentiation programs. Nature Cell Biology | go.nature.com/3TlIc3C

🛡️ Dr. Dong Hu and scientists at Mayo Clinic demonstrate that p95HER2, a truncated form of HER2, drives immune evasion in HER2-positive female #BreastCancer, enhancing tumor growth and conferring therapy resistance. Nature Cancer | go.nature.com/3TmgrYz

A team of researchers in China have shown that FRMD8 inhibits tumor #metastasis in BRCA1-associated triple-negative #BreastCancer by negatively regulating transmembrane TNF-α. 📖 Read the study: bit.ly/46tI61m

New work led by Drs. Silvia Formenti, Simon Knott, and Lorenzo Galluzzi (Lorenzo Galluzzi) shows that IL-17A-secreting γδ T cells promote resistance to CDK4/CDK6 inhibitors in HR+HER2− #BreastCancer via CX3CR1+ macrophages. Read the Nature Cancer study: go.nature.com/4kqPMVq

Chemotherapy resistance significantly limits the clinical efficacy of chemotherapy in #TNBC. A new study shows that the deubiquitinating enzyme USP44 is a contributor to #chemoresistance via destabilization of EZH2.

A new study has identified critical genes involved in #BreastCancer-associated platelet-related #exosomes. 🔬 It suggests that #PLA2G4A plays a crucial role in the progression of the disease, acting as a potential tumor-suppressor gene. bit.ly/4eHI9IY

A new study investigated whether primary #TumorResection improves the survival of de novo stage IV #BreastCancer patients. Although it did not prolong overall survival, it improved local control and might benefit a subset of patients. Read the British Journal of Cancer study:

Inhibiting #EMT and vasculogenic mimicry represents a promising therapeutic strategy for #TNBC. The proposed combination therapy strategy suppressed tumor growth and lung metastasis by inducing apoptosis in TNBC. 💡 Find out more: go.nature.com/4kDWXKe

Led by Dr. Vanessa Dumeaux (Vanessa Dumeaux @[email protected]), this work uncovers molecular programs underlying in-situ versus invasive #BreastCancer recurrence, with mutations affecting tissue structural maintenance and cell-cycle/genome-stability pathways. 🧬 Learn more: bit.ly/3TKnzya

Collaborators including Dr. Jueyu Zhou provide evidence that DHX9 hinders the transcription of BECN1 by recruiting HDAC5 to its promoter mediating the deacetylation of histone H3 and accelerates #BreastCancer progression. 📈 🔗 Read about it here: go.nature.com/40V0XyR

This research, led by Dr. Jonkers and Catrin Lutz, establishes a comprehensive and valuable resource of well-characterized orthotopic cell line–derived xenograft models for #BreastCancer research. 🧫 💡 More in Cancer Research | bit.ly/3UgCWOZ

Findings from this Scientific Reports study highlight the overexpression and functional involvement of Banf1 in #TNBC progression and suggests that it may have potential as a novel anti-cancer target. 🎯 Dr. Emma Bolderson and colleagues led this study. 👇 go.nature.com/4eTgDIC

💉 The authors generated orthotopic cell line–derived xenograft models from breast cancer cell lines using both #mammary intraductal injections and fat pad transplantations. Cancer Research | bit.ly/3IDH1KG

The FDA granted breakthrough therapy designation to first-line treatment with trastuzumab deruxtecan (Enhertu) plus pertuzumab (Perjeta) for unresectable or metastatic HER2+ #BreastCancer. Check out this CURE Today interview where Dr. Sara Tolaney (Sara Tolaney) discusses the

🛡️ The authors review the metabolic strategies that #HER2+ breast cancer cells adopt to enable trastuzumab resistance, grouping them into a structured classification that takes into account their functional nature. 📖 bit.ly/451bI3S

💉 Researchers designed a puncture-delivered tumor implant that enables the sustained release of nanoparticles through matrix #metalloproteinase-responsive degradation, providing a practical immunotherapy strategy for breast cancer. ACS Nano | bit.ly/44OQLdP

🛡️ Researchers identify a hypoxia-driven feedforward loop wherein cancer-associated fibroblasts-derived exosomal circSTAT3 promotes #TNBC stemness and chemoresistance via miR-671-5p/NOTCH1 signaling 🔗 bit.ly/453I6TI